Interestingly, a switch between RBFOX2 (also called RBM9) and ESRP1/2 splicing factors has been involved in epithelial to mesenchymal transition (EMT) (25), and EMT was previously found associated with Doxo resistance in breast cancer (26–28). Here, ESRP1 is linked to breast cancer.